Andere talen Caplin Point Laboratories Limited

Aandelen

524742

INE475E01026

Beurs gesloten - Bombay S.E. Andere beurzen 12:00:49 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.299 ^INR	-2,43%		-3,82%	-4,23%

28/03	Caplin Point-eenheid ontvangt goedkeuring van de Amerikaanse FDA voor oogbehandelingsmedicijn	MT
28/03	Caplin Steriles Limited, een dochteronderneming van Caplin Point Laboratories Limited krijgt goedkeuring van USFDA voor Ketorolac Tromethamine oogheelkundige oplossing	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution	16/04
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication	28/03
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution	28/03
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India	27/03
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations	27/03
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India	08/01
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug	08/01
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D	14/12
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023	22-09-23
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA	04-09-23
Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07-08-23
Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023	07-08-23
Caplin Point Laboratories to Incorporate Step-Down Subsidiary in US	03-08-23
Caplin Point Unit Gets US FDA Nod for Muscle Relaxant	12-06-23
Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP	12-06-23
Caplin Point Gets Four Observations from US FDA After Inspection of Injectable Unit at Gummidipoondi, India	01-06-23
Caplin Point Laboratories Limited Approves Interim Dividend for the Financial Year 2022-23	27-05-23
Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	27-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Caplin Point Laboratories Limited

Aandelen

524742

INE475E01026

Andere talen

Filters